Claims
- 1. A method for forming an immunogenic composition, comprising:
- providing an expression vector containing an entire DNA sequence shown contiguously in FIG. 3, 3A and 3B encoding an entire P2 outer membrane protein of a strain of Haemophilus influenzae type b under control of a promoter,
- transforming the expression vector into a bacterial strain,
- expressing the entire P2 outer membrane protein encoded by said DNA sequence to produce a recombinantly expressed P2 outer membrane protein from a Haemophilus influenzae type b strain having an entire derived amino acid sequence of FIG. 3,
- isolating and purifying the recombinantly expressed P2 outer membrane protein,
- conjugating the isolated and purified P2 outer membrane protein to a capsular polysaccharide moiety of a Haemophilus organism which is a PRP of Haemophilus influenzae type b to form a conjugate molecule, and
- formulating the conjugate molecule as an immunogenic composition.
- 2. A conjugate molecule, consisting of a synthetic peptide having an amino acid sequence which is either the N-terminal amino acid residues 1 to 14 or the C-terminal amino acid residues 314 to 341 of the P2 outer membrane protein of a strain of Haemophilus influenzae type b having the derived amino acid sequence shown contiguously in FIG. 3, 3A and 3B and a carrier protein for said synthetic peptide.
- 3. A method for forming a conjugate molecule, comprising:
- providing an expression vector containing an entire DNA sequence shown contiguously in FIG. 3, 3A and 3B encoding an entire P2 outer membrane protein of a strain of Haemophilus influenzae type b under control of a promoter,
- transforming the expression vector into a bacterial strain,
- expressing the P2 outer membrane protein encoded by said DNA sequence to produce a recombinantly expressed P2 outer membrane protein from a strain of Haemophilus influenzae type b having an entire derived amino acid sequence of FIG. 3, and
- conjugating the P2 outer membrane protein to a capsular polysaccharide moiety of a Haemophilus organism which is a PRP of Haemophilus influenzae type b.
- 4. The method of claim 3 wherein said Haemophilus influenzae type b is selected from the group consisting of MinnA, Durst, OMP subtype 6U and OMP subtype 3L strains.
- 5. The method of claim 1 wherein said PRP of Haemophilus influenzae type b has been heat treated to attain a molecular size of 15,000 to 40,000 daltons.
- 6. The method of claim 3 wherein said PRP of Haemophilus influenzae type b has been heat treated to attain a molecular size of 15,000 to 40,000 daltons.
Priority Claims (2)
Number |
Date |
Country |
Kind |
8830124 |
Dec 1988 |
GBX |
|
8902178 |
Feb 1989 |
GBX |
|
Parent Case Info
This is a continuation of U.S. patent application Ser. No. 853,015 filed Mar. 18,1992, now abandoned, which itself is a continuation of application Ser. No. 456,000 filed Dec. 22, 1989 now abandoned.
US Referenced Citations (2)
Number |
Name |
Date |
Kind |
4762713 |
Anderson et al. |
Aug 1988 |
|
5098997 |
Anilionis et al. |
Mar 1992 |
|
Non-Patent Literature Citations (2)
Entry |
Munson et al., J. Clin. Invest., vol. 72, 1983, pp. 677-684. |
J.Clin.Invest, vol. 72, Aug. 1983, pp. 677-684, Robert S. Munson Jr. et al., "Purification and Comparison of Outer Membrane Protein P2 from Haemophilus Influenzae Type b Isolates". |
Continuations (2)
|
Number |
Date |
Country |
Parent |
853015 |
Mar 1992 |
|
Parent |
456000 |
Dec 1989 |
|